This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fennell, D. A. Articles by Rudd, R. Search for Related Content PubMed PubMed Citation Articles by Fennell, D. A. Articles by Rudd, R. Social Bookmarking                            What's this?

Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials

From the Lung Cancer and Mesothelioma Unit, Department of Medical Oncology, and the Institute of Cell and Molecular Science—Pathology, St Bartholomew’s Hospital; London Lung Cancer Group, London, United Kingdom

Address reprint requests to Dean A. Fennell, MD, West Smithfield, London EC1A 7BE, United Kingdom; e-mail: d.a.fennell{at}qmul.ac.uk

PURPOSE: Malignant pleural mesothelioma (MPM) carries a poor prognosis due to chemoresistance. The European Organisation for Research and Treatment of Cancer (EORTC) prognostic model was reported to predict survival in MPM. Our retrospective analysis set out to test the validity of the model as a prognostic tool in patients treated in three phase II trials at St Bartholomew’s Hospital (London, United Kingdom) between 1999 and 2003.

PATIENTS AND METHODS: A total of 145 patients were treated in three phase II trials; vinorelbine (VIN; 70 patients), vinorelbine/oxaliplatin (VO; 26 patients), and irinotecan/cisplatin/mitomycin C (IPM; 49 patients). Two subgroups, high-risk and low-risk, were defined by EORTC prognostic score (EPS). EPS was determined by a five-parameter model incorporating age, sex, histology, probability of diagnosis, and leukocyte count. An EPS cutoff of less than 1.27 (low risk) or more than 1.27 (high risk) was used to stratify Kaplan-Meier survival curves. Each of the EPS variables exhibited either trends or significant stratification of overall survival (OS).

RESULTS: Multivariate analysis confirmed leukocyte count, Eastern Cooperative Oncology Group performance status, and sarcomatous histology as independent prognostic variables. EPS stratified OS in both individual and pooled trial datasets. No association between objective tumor response and EPS classification was identified by multinomial logistic regression. EPS stratified progression-free survival for the VO and IPM cohorts, but not for VIN.

CONCLUSION: This study validates the EPS system as a robust tool for stratifying small trials into low- and high-risk subgroups. EPS should facilitate patient selection and analysis in randomized clinical trials.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Ray and H. L. Kindler Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment Chest, September 1, 2009; 136(3): 888 - 896. [Abstract] [Full Text] [PDF]

				A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler Malignant Pleural Mesothelioma J. Clin. Oncol., April 20, 2009; 27(12): 2081 - 2090. [Abstract] [Full Text] [PDF]

				A. Bottomley, C. Coens, F. Efficace, R. Gaafar, C. Manegold, S. Burgers, M. Vincent, C. Legrand, and J. P. van Meerbeeck Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., December 20, 2007; 25(36): 5770 - 5776. [Abstract] [Full Text] [PDF]

				R. Sposto, W. B. London, and T. A. Alonzo Criteria for Optimizing Prognostic Risk Groups in Pediatric Cancer: Analysis of Data From the Children's Oncology Group J. Clin. Oncol., May 20, 2007; 25(15): 2070 - 2077. [Abstract] [Full Text] [PDF]

				I. Opitz, P. Kestenholz, D. Lardinois, M. Muller, V. Rousson, D. Schneiter, R. Stahel, and W. Weder Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg., April 1, 2006; 29(4): 579 - 584. [Abstract] [Full Text] [PDF]

				A. Bottomley, R. Gaafa, C. Manegold, S. Burgers, C. Coens, C. Legrand, M. Vincent, G. Giaccone, and J. Van Meerbeeck Short-Term Treatment-Related Symptoms and Quality of Life: Results From an International Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study J. Clin. Oncol., March 20, 2006; 24(9): 1435 - 1442. [Abstract] [Full Text] [PDF]